Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Hld Ag Div Rt (OP: RHHVF )

279.71 UNCHANGED
Streaming Delayed Price Updated: 2:15 PM EDT, Mar 17, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 279.71
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 279.71
Today's Range 279.71 - 279.71
52wk Range 275.50 - 430.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
FDA Casts Doubts Over Roche's Polivy Label Expansion For Untreated Lymphoma Setting
 
Via Benzinga
Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo
 
Via Benzinga

Performance

YTD
-10.11%
-10.11%
1 Month
-7.21%
-7.21%
3 Month
-12.84%
-12.84%
6 Month
-13.18%
-13.18%
1 Year
-29.90%
-29.90%

More News

Read More
Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines
Via Benzinga
New Data Shows Roche's Vabysmo Improves Vision, Retinal Fluid In Retinal Disorder
Via Benzinga
Roche Touts Positive Crovalimab Data From Late-Stage Study In Rare Blood Condition
Via Benzinga
Roche Flags Lower 2023 Sales On Declining Demand For COVID-19 Treatment, Diagnostics
Via Benzinga
Genentech's Tecentriq Plus Avastin Combo Cuts Risk of Cancer Returning In Early-Stage Liver Cancer
Via Benzinga
Europe Approves Xofluza, Roche's Revolutionary Influenza Antiviral with New Mechanism
Via Benzinga
Roche's Investigational Lymphoma Candidate Goes Under FDA Priority Review
Via Benzinga
Roche's Follicular Lymphoma Therapy Scores FDA Approval
Via Benzinga
FDA Approves Roche's Tocilizumab As First Monoclonal Antibody For COVID-19 Treatment
Via Benzinga
Roche Presents New Data Demonstrating Potential Benefit Of Two Lymphoma Candidates
Via Benzinga
After 16 Years, Roche's Pharma Division Head Decides To Step Down
Via Benzinga
Replimune Shares Surge After Early Data From Pretreated Melanoma Patients
Via Benzinga
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says
Via Benzinga
FDA Gives Emergency Use Nod To Roche's Monkeypox Test
Via Benzinga
Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage
Via Benzinga
Roche Inks Second Drug Discovery Deal With Jnana Therapeutics
Via Benzinga
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
Via Benzinga
Roche's Another Alzheimer's Hopeful Flops In Phase 3 Program, Second Trial Setback Within Months
Via Benzinga
Roche Posts Lower Quarterly Sales As Demand For COVID Products Slide
Via Benzinga
Roche's Muscular Atrophy Treatment Improves Motor Function In Pretreated Patients
Via Benzinga
Roche To Introduce Next-Generation Portfolio Of COVID-19 Rapid Tests
Via Benzinga
EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility
Via Benzinga
FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.